Description
A CXCR3 antagonist (Ki = 3.6 nM in a radioligand binding assay); inhibits CXCL10- or CXCL11-induced calcium mobilization in RBL cells expressing human CXCR3 (IC50 = 7 nM for both); inhibits CXCL11-induced chemotaxis of CXCR3-expressing H9 cells and PHA/IL-2 T cells (IC50s = 3.9 and 6.6 nM, respectively); reduces peritoneal lymphocyte migration in a mouse model of peritonitis at 100 mg/kg; reduces the size and number of aortic arch atherosclerotic lesions in Ldlr-/- mice; reduces spinal cord microglial activation and levels of CXCL4, CXCL9, and CXCL10 and decreases thermal and mechanical hyperalgesia in a rat model of chronic constriction injury-induced neuropathic pain
Formal name: N-[(1R)-1-[3-(4-ethoxyphenyl)-3,4-dihydro-4-oxopyrido[2,3-d]pyrimidin-2-yl]ethyl]-4-fluoro-N-(3-pyridinylmethyl)-3-(trifluoromethyl)benzeneacetamide
Synonyms:
Molecular weight: 605.6
CAS: 855527-92-3
Purity: ≥98%
Formulation: A solid